Last reviewed · How we verify
NCT06282224
Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery
NA trial testing Performing endoscopic transnasal skull base surgery with AR-integrated endoscope in Pituitary Neoplasms in 10 participants. Currently enrolling.
11 January 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 22 January 2024 |
| Primary completion | 11 January 2025 |
| Estimated completion | 11 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
Conditions studied
- Pituitary Neoplasms — all drugs for Pituitary Neoplasms →
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
Eligibility, any sex, with Pituitary Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
"For lesions in the skull base, including meningiomas, chordomas and pituitary tumors, endoscopic surgery has replaced traditional microscopes as the mainstream procedure. Although neurosurgeons can enlarge the surgical area using a neuroendoscope, it does not provide any information on the morphology and location of anatomical structures beneath visible surfaces. Due to the complex anatomical relationships of adjacent structures in the skull base, lesions occurring here are often located deep within anatomy that is difficult to fully expose and remove with endoscopic surgery alone. Especially when dealing with larger tumors that surround major arteries and nerves, limited visibility at surface level can easily damage blood vessels or nerves causing complications such as bleeding during or after surgery, deformities or functional impairments. The purpose of this study is to explore how augmented reality (AR) technology can highlight important anatomical structures in a neuroendoscope's field of view to optimize surgical visibility beyond what is possible with just an endoscope alone. This will make it easier for surgeons to distinguish deeper anatomical structures and reduce intraoperative and postoperative complications associated with endoscopic surgery."
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06282224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pituitary Neoplasms
Currently open trials in the same condition.
- NCT03665064 — Long Term Outcome Study in Patients With Pituitary Disorders · active not recruiting
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06282224 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing